Excess Mortality in the Vaccination Era in the United States, By State and 6-Month Period ========================================================================================= * Jeremy Samuel Faust * Benjamin Renton * Chengan Du * Alexander Junxiang Chen * Shu-Xia Li * Zhenqiu Lin * Harlan M. Krumholz ## Abstract **Introduction** The US continued to record all-cause excess mortality after the rollout of vaccines. We sought to quantify excess mortality by state and compare these rates to primary series vaccination completion levels. **Methods** Observational cohort, US and state-level data. Expected monthly deaths were modeled using pre-pandemic US and state-level data (2015-2020). Mortality data was accessed from CDC public reporting. **Results** We find that in a two-year period since the rollout of vaccines, the US recorded >874,000 excess deaths. Vaccination rates and excess mortality were most strongly correlated in first two periods before the Omicron variant. **Conclusion** The association between vaccination and lower excess mortality rates was strongest in 2021 and early 2022, prior to high population rates of infection-acquired immunity. The findings underscore the benefits of the rapid vaccination rollout campaign and the continued need to boost at-risk populations. ## Introduction Vaccination has been shown to reduce COVID-19 mortality, the major driver of all-cause excess mortality.1 Both vaccination rates and excess mortality has varied across the US.2 We sought to determine the relationship of state-level excess deaths and vaccination rates across different waves of the pandemic. We hypothesized there would be a strong relationship between vaccination rates and excess mortality among US adults and this relationship would weaken as more people had been infected with SARS-CoV-2. ## Methods As previously, we applied seasonal autoregressive integrated moving average (sARIMA) modeling to monthly all-cause death data from the Centers for Disease Control and Prevention and state population counts (2014-2020) to create monthly population and expected death estimates for the study period (January 2021-December 2022), correcting for population decreases owing to cumulative pandemic-associated excess deaths.3,4 Excess deaths were calculated (observed minus expected deaths). The study was divided into four six-month periods: January 1-June 30, 2021 (Early Vaccine Rollout), July 1-December 31, 2021 (Delta), January 1-June 30, 2022 (Omicron 1), July 1-December 31, 2022 (Omicron 2). For all states, expected deaths for three age groups of adults were modeled (18-49, 50-64, and ≥65 years), which were then combined, creating a composite excess mortality figure. Vaccination rates were calculated as the primary series completion rate for each age group and state at the middle date of each period.2 Analyses were conducted with R version 4.0.3. This study used publicly available data and was not subject to institutional review approval per HHS regulation 45-CFR-46.101(c). ## Results During the total two-year study period (vaccine era), the US recorded 874,688 (95% CI, 751,497-997,879) excess deaths. There were 219,239 (95% CI, 175,703-262,776) excess deaths during the Early Vaccine Rollout, 335,582 (95% CI, 291,680-379,484) excess deaths during the Delta, 196,788 (95% CI, 152,887-240,689) excess deaths during the Omicron 1 and 123,078 (95% CI, 80,063-166,094) excess deaths during Omicron the Omicron 2 periods, corresponding to 85, 130, 76 and 47 excess deaths per 100,000 persons, respectively. Vaccination rates and excess mortality were inversely correlated in the first three 6-month periods (January 2021-June 2022), with the strongest correlations observed during the Delta period (Figures 1 and 2). There was no observed correlation during the later Omicron period (July-December, 2022) (Figures 1 and 2). These findings were seen in all adults (Figure), including among adults ages ≥65. ![Figure 1](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/03/08/2023.03.07.23286927/F1.medium.gif) [Figure 1](http://medrxiv.org/content/early/2023/03/08/2023.03.07.23286927/F1) Figure 1 ![Figure 2](http://medrxiv.org/https://www.medrxiv.org/content/medrxiv/early/2023/03/08/2023.03.07.23286927/F2.medium.gif) [Figure 2](http://medrxiv.org/content/early/2023/03/08/2023.03.07.23286927/F2) Figure 2 ## Discussion There were differences in excess mortality across US states during from January 2021-December 2022 which varied by vaccination rate. A stronger relationship was observed earlier in the vaccination period of the pandemic, when natural immunity was lowest. The loss of an association between excess mortality and vaccination rates later in the study (including in adults ages ≥65) argues for the necessity of boosting at-risk populations, given what is known about booster effectiveness.5 The results also imply that the campaign to rapidly vaccinate the population prior to high rates of immunity acquired by infection saved many lives. This study also suggests the potential lives that could have been saved if vaccination rates had been higher, were this relationship to be causal, a reasonable assumption based on the vaccine trials.5,6 Limitations include its observational nature and its use of provisional mortality data. ## Data Availability All data produced in the present study are available upon reasonable request to the authors ## Author Contributions Dr. Faust and Mr. Renton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. ### Concept and design Faust, Du, Krumholz, Renton. *Acquisition, analysis, or interpretation of data:* All authors. *Drafting of the manuscript:* Renton, Faust. ### Critical revision of the manuscript for important intellectual content All authors. ### Statistical analysis Faust, Du, Li, Lin, Renton. *Administrative, technical, or material support:* Faust, Du, Lin. *Supervision:* Faust, Krumholz. ### Data visualization Renton. ## Conflict of Interest Disclosures Dr. Krumholz reported receiving consulting fees from UnitedHealth, Element Science, Aetna, Reality Labs, F-Prime, and Tesseract/4Catalyst; serving as an expert witness for Martin/Baughman law firm, Arnold and Porter law firm, and Siegfried and Jensen law firm; being a cofounder of Hugo Health, a personal health information platform; being a cofounder of Refactor Health, an enterprise health care, artificial intelligence–augmented data management company; receiving contracts from the Centers for Medicare & Medicaid Services through Yale New Haven Hospital to develop and maintain performance measures that are publicly reported; and receiving grants from Johnson & Johnson outside the submitted work. No other disclosures were reported. * Received March 7, 2023. * Revision received March 7, 2023. * Accepted March 8, 2023. * © 2023, Posted by Cold Spring Harbor Laboratory This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/) ## References 1. 1.Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. The Lancet Infectious Diseases. 2022;22(9):1293–1302. doi:10.1016/S1473-3099(22)00320-6 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(22)00320-6&link_type=DOI) 2. 2.COVID-19 Vaccinations in the United States,Jurisdiction | Data | Centers for Disease Control and Prevention. Accessed March 6, 2023. [https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc](https://data.cdc.gov/Vaccinations/COVID-19-Vaccinations-in-the-United-States-Jurisdi/unsk-b7fc) 3. 3.Faust JS, D. C, Liang C, et al. Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19. JAMA. 2022;328(1):74–76. doi:10.1001/jama.2022.8045 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2022.8045&link_type=DOI) 4. 4.Centers for Disease Control and Prevention. Provisional Mortality Statistics, CDC WONDER. Accessed December 6, 2022. [https://wonder.cdc.gov/mcd-icd10.html](https://wonder.cdc.gov/mcd-icd10.html) 5. 5.Lin DY, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. JAMA. 2022;328(14):1415–1426. doi:10.1001/jama.2022.17876 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2022.17876&link_type=DOI) 6. 6.Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022. JAMA. 2023;329(1):92–94. doi:10.1001/jama.2022.21795 [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2022.21795&link_type=DOI)